Purchase Order 75N91019P00606

<p>The National Institute on Aging awarded a purchase order to Nexcelom Bioscience LLC for a Cellometer Auto 2000 cell counter system valued at $12,680.00 on June 13, 2017. Performance takes place in Lawrence, Massachusetts. The order is priced firm fixed price with no set-aside applied.</p>

<p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a purchase order to Nexcelom Bioscience LLC for $12,180.00 on July 3, 2018, for a Cellometer Auto 2000 Automatic Cell Viability Counter System. The order carries no set-aside designation. Place of performance is Lawrence, Massachusetts. The ultimate completion date is June 26, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Nexcelom Bioscience LLC for $13,995.00 on September 7, 2017, with completion targeted for October 9, 2017. Work is performed in Bethesda, Maryland. The order is for firm fixed price commercial scientific equipment or related supplies, consistent with Nexcelom's product portfolio of cell analysis and imaging cytometry devices used in biomedical research.</p>

This is a $12,180 firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, to Nexcelom Bioscience LLC, a small business manufacturer and developer of image cytometry products for cell analysis in life science and biomedical research. The contract is for the provision of a Cellometer Auto 2000 cell counter, with a total small business set-aside. Nexcelom Bioscience LLC has previously...

<p>The National Cancer Institute awarded a purchase order to Nexcelom Bioscience LLC for a Celigo Image Cytometer System on September 13, 2018, with a ceiling value of $159,000. The order is set aside for Total Small Business. Performance will take place in Lawrence, Massachusetts, with an ultimate completion date of November 12, 2018. The acquisition is firm fixed price. The underlying solicitation was posted August 6, 2018, with a due date of August 24, 2018.</p>

<p>The National Cancer Institute awarded a purchase order to Nexcelom Bioscience LLC for $139,000.00 on September 5, 2018, for acquisition of a Nexcelom Bioscience Celigo Imaging Cytometer. Place of performance is Lawrence, Massachusetts. The order carries no set-aside designation and has a firm fixed price. Ultimate completion date is October 3, 2018. The award derives from a pre-solicitation posted August 9, 2018, with a due date of August 24, 2018.</p>

<p>The National Cancer Institute awarded a purchase order to Nexcelom Bioscience LLC for $12,180.00 on July 30, 2020, with an ultimate completion date of August 31, 2020. The order procures scientific equipment on a firm fixed price basis. Performance occurs at Nexcelom's facility in Lawrence, Massachusetts. No set-aside category was applied.</p>

<p>The National Cancer Institute awarded a purchase order to Nexcelom Bioscience LLC for $14,955.00 on September 3, 2019, for lab equipment. The order carries no set-aside designation. Performance is located in Lawrence, Massachusetts, with an ultimate completion date of September 30, 2019. The purchase order is priced on a firm fixed price basis for commercial laboratory equipment, including cell analysis and imaging cytometry products used in biomedical research.</p>

The National Cancer Institute awarded a purchase order to Nexcelom Bioscience LLC for a Celigo S Imaging Cytometer System valued at $115,000 on September 18, 2019. No set-aside was used. Performance is located in Lawrence, Massachusetts. The system is a cell imaging cytometer for life science and biomedical research applications. The order was to be completed by January 18, 2020. The procurement originated from a pre-solicitation posted June 25, 2019 with a July 5, 2019 submission deadline.

<p>The National Cancer Institute awarded a purchase order to Nexcelom Bioscience LLC on July 19, 2018, with a ceiling value of $12,280.00. Performance is located in Lawrence, Massachusetts. The order is firm fixed price with no small business set-aside applied. Ultimate completion is scheduled for August 18, 2018.</p>